[Skip to Navigation]
Sign In
Invited Commentary
October 2017

Active Surveillance for Low-Risk Prostate Cancer—An Evolving International Standard of Care

Author Affiliations
  • 1Department of Urology, University of California–San Francisco
  • 2Department of Epidemiology & Biostatistics, University of California–San Francisco
  • 3Helen Diller Family Comprehensive Cancer Center, University of California–San Francisco
JAMA Oncol. 2017;3(10):1398-1399. doi:10.1001/jamaoncol.2016.3179

In 2016, active surveillance has finally become standard of care for low-risk prostate cancer in the United States. Recent articles from prospective, community-based registries have shown uptake of active surveillance skyrocketing to 40% to 50% for low-risk disease in the current decade, up from rates that historically rarely exceeded 10%.1,2 A growing body of evidence indicates that active surveillance can preserve quality of life without posing substantial short- to intermediate-term oncologic risk. Based on this evidence, a recent guideline endorsed by the American Society of Clinical Oncology (ASCO) now clearly states that surveillance is not merely an option for men with low-risk disease but rather is the preferred alternative for any clinically localized, Gleason 3 + 3 cancer.3

Add or change institution